European real estate markets are stabilising following a sharp valuation correction, but today’s dislocation, driven by a reset in interest rates, shifts in occupier behaviour, and constrained capital availability, is creating a rare and differentiated opportunity set…
Hayfin today announces the opening of a new office in Seoul, further expanding its presence in Asia-Pacific and reinforcing its long-term commitment to the Korean market…
Hayfin has been named Private Credit Lender of the Year at the ION Analytics Mergermarket European Private Equity Awards 2026…
The €15 billion final close of the Hayfin Direct Lending Fund V was a milestone for our firm. But perhaps more interesting than the size of the fund was what we learned from the investors behind it…
The complexity premium is the additional return available on capital solutions relative to traditional lending. While it can be difficult to disentangle from credit risk and other risk premia, we define it as where nuance in the asset, business, process or structure limits conventional lender participation, creating the opportunity to earn a premium return to a situation with similar credit risk but without the nuance…
Hayfin has led as sole-lender the debt financing to support a new financing arrangement for Condis Supermercats (“Condis”), the leading proximity supermarket group in Catalonia. The funding will be provided through a €305m senior-secured unitranche facility, backed by the company’s institutional shareholder Portobello Capital (“Portobello”)…
Hayfin is pleased to announce that it acted as sole lender in the refinancing of Norvestor-backed Serwent, a Norway-based provider of underground infrastructure maintenance (UIM) services…
Payment-in-kind is one of the most scrutinised features in private credit today – and one of the most misunderstood. The labels we reach for don’t always tell the full story…
Healthcare has never been more essential, or more capital-intensive. An ageing global population, rising chronic disease burden, and a continued wave of scientific innovation are driving demand for therapeutics, devices, and services to record levels, largely independent of the economic cycle…
Whoops! Something went wrong.
